[
    "{\"step_by_step_thinking\": \"Document [3] states that co-loss of BRCA2 and RB1 in prostate cancer is associated with a more aggressive disease phenotype and likely worse prognosis. Document [1] also reports a case of a patient with BRCA2 and RB1 co-loss who died 2 years 6 months after being diagnosed with prostate cancer. Document [25] also mentions that BRCA2 mutation carriers have a shorter survival time. These documents suggest that co-loss of BRCA2 and RB1 is associated with a worse prognosis for prostate cancer patients.\", \"answer_choice\": \"B\"}"
]